PDMR Dealings

RNS Number : 5589C

Oxford Biomedica PLC

12 October 2022

 

PDMR Dealings

Oxford, UK  - 12 October 2022:   Oxford Biomedica plc ("Oxford Biomedica" or " the Company") (LSE:OXB), a leading gene and cell therapy group, today announces   that Non-Executive Directors Dr. Michael Hayden, Dr Heather Preston, Dr. Sam Rasty and Catherine Moukheibir have purchased ordinary shares in the Company pursuant to a trading plan put in place on 7 October 2022.  

By way of background, and as stated in the Oxford Biomedica 2021 Remuneration Policy which was approved at the 2021 Annual General Meeting, an additional fee of up to 50,000 per annum may be paid to any Non-Executive Director recruited from or based outside of the UK to reflect market levels of remuneration for Non-Executive Directors not based in the UK, subject to their agreement that the after tax amount of this additional fee will be used to acquire Oxford Biomedica shares at market value, which must be retained for at least 12 months from acquisition. The ordinary shares were all purchased as 317p and the number of ordinary shares purchased along with further information is set out in the table below:

Name of PDMR	Number of o rdinary shares purchased	Number of ordinary shares now held	T otal number of ordinary shares held as a percentage of the Company's share capital
Dr. M ichael Hayden	9,379	11,289	0.012%
Dr. Heather Preston	9,379	11,614	0.012%
Dr. Sam Rasty	9,379	11,614	0.012%
C athrine Moukheibir	8,910	11,846	0.012%

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of ordinary shares purchased.

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")
a)	Name	Dr. Michael Hayden
2.	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	P urchase of shares
c)	Currency	GBP - British pound
d)	Price(s) and volumes(s)	Price(s) Volume(s) £3.17 9,379
e)	Aggregated information -  Aggregate volume -  Aggregated total	9,379 £29,999.57
f)	Date of the transaction	2022-10-11
g)	Place of the transaction	London Stock Exchange, Main Market (XLON)

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")
a)	Name	Dr. Heather Preston
2.	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	P urchase of shares
c)	Currency	GBP - British pound
d)	Price(s) and volumes(s)	Price(s) Volume(s) £3.17 9,379
e)	Aggregated information -  Aggregate volume -  Aggregated total	9,379 £29,999.57
f)	Date of the transaction	2022-10-11
g)	Place of the transaction	London Stock Exchange, Main Market (XLON)

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")
a)	Name	Dr. Sam Rasty
2.	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	P urchase of shares
c)	Currency	GBP - British pound
d)	Price(s) and volumes(s)	Price(s) Volume(s) £3.17 9,379
e)	Aggregated information -  Aggregate volume -  Aggregated total	9,379 £29,999.57
f)	Date of the transaction	2022-10-11
g)	Place of the transaction	London Stock Exchange, Main Market (XLON)

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")
a)	Name	Catherine Moukheibir
2.	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	P urchase of shares
c)	Currency	GBP - British pound
d)	Price(s) and volumes(s)	Price(s) Volume(s) £3.17 8,910
e)	Aggregated information -  Aggregate volume -  Aggregated total	8,910 £28,499.59
f)	Date of the transaction	2022-10-11
g)	Place of the transaction	London Stock Exchange, Main Market (XLON)

-Ends-

For further information, please contact:
Oxford Biomedica plc: Natalie Walter, Company Secretary	Tel: [phone]

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, and is working on programmes from pre-clinical to commercial stage across a range of therapeutic areas with global partners.

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

Further information is available at www.oxb.com .

 

END

 

 

DSHFFFLIITLLLIF